Broomrape (Cistanche spp. / Orobanche spp.) as a Dietary Supplement and Natural Ingredient
1. Identity: Botanical Names, Sources, and Common Forms
1.1 Taxonomy and Nomenclature
The common name "broomrape" encompasses multiple genera and species within the family Orobanchaceae, all of which are obligate or near-obligate holoparasites that lack chlorophyll and derive nutrients from host plant roots. Orobanche, colloquially known as broomrape, is a genus of over 100 chlorophyll-deficient obligate plants. As a dietary supplement and medicinal botanical, two groups are of primary relevance:
- Cistanche spp. — The predominant supplement-grade broomrape. The two species authenticated in the Pharmacopoeia of the People's Republic of China are Cistanche deserticola Y. C. Ma and Cistanche tubulosa (Schenk) R. Wight (family Orobanchaceae). Cistanches Herba (Roucongrong in Chinese), a widely utilized traditional Chinese medicine (TCM), is derived from the dried succulent stems of Cistanche deserticola (Y. C. Ma) and Cistanche tubulosa (Schenk) Wight, both officially authenticated in the Pharmacopoeia of the People's Republic of China.
- Orobanche spp. — The "true broomrapes" of European, Middle Eastern, and some Asian traditional medicine. Documented species used medicinally include O. major, O. minor, O. crenata, O. coerulescens, O. cumana, and others. A number of species appear to have been used similarly in different traditions, including O. major, O. minor (Greater and Lesser Broomrape in the West), O. caryophyllacea (Clove-Scented Broomrape), O. rubra (Red Broomrape), and O. purpurea (Purple Broomrape).
1.2 Common Names and Synonyms
Cistanche tubulosa is known as Rou Cong Rong, Desert Hyacinth, and Ginseng of the Desert; other less common names include Cistanches Caulis, Desert-Broomrape, Fleshy Stem of Broomrape, Herba Cistanche, and Suosuo Dayun. The Chinese name translates literally to "fleshy broomrape." Because of its efficacy and moderate tonic character, Herba Cistanches is widely accepted and has earned the honor of "Ginseng in the deserts."
1.3 Botanical Source and Habitat
The dried succulent stem of C. tubulosa (Schenk) Wight has long been used as herbal medicine in China and other regions of Asia for its tonifying properties. Cistanche species are parasitic on the roots of desert shrubs — notably saxaul (Haloxylon ammodendron) — in arid zones of northern China, Mongolia, and Central Asia. Cistanche deserticola is an endangered plant, which is why many cistanche supplement manufacturers do not use it. As a result, C. tubulosa has become the primary commercial species.
1.4 Forms and Preparations
Cistanche is marketed in several standardized and non-standardized forms:
- Dried stem slices — used in traditional decoctions.
- Standardized extracts (capsules/tablets) — typically standardized to a minimum content of phenylethanoid glycosides (PhGs), especially echinacoside. The characteristic components of the extract are phenylethanoid glycosides (at least 70% of the NF), in particular echinacoside (25–45% of the NF).
- Water extract powders — the basis for the novel food application reviewed by EFSA.
- Wine-processed (steamed) preparations — a traditional processing technique wherein the herb is steamed with rice wine, which modifies polysaccharide molecular weight and reportedly enhances bioactivity. Wine processing significantly modified the polysaccharides, increasing polysaccharide content, markedly reducing molecular weight, and altering monosaccharide composition.
- Named pharmaceutical/nutraceutical products — for example, Memoregain® (Cistanche tubulosa glycoside capsules), which has been approved as a prescription drug in China for vascular dementia. The NF has been authorised as a prescription drug in China in 2005 for the treatment of vascular dementia.
According to the Chinese Pharmacopoeia, at least 0.3% of the total contents of echinacoside and acteoside for medical application should be determined from the dried stem of C. deserticola by the high-performance liquid chromatography (HPLC) method.
2. Traditional and Historical Use
2.1 Traditional Chinese Medicine (TCM)
Cistanche tubulosa is a parasitic flower that has been used in Traditional Chinese Medicine for thousands of years; native to Mongolia, it is a nootropic and an adaptogen. Cistanche was originally recorded in the Classic of Herbal Medicine, written between approximately 200 and 250 AD, as an herb that can regulate "five (viscera) strains and seven impairments."
Plants of the genus Cistanche have been used in China and other eastern Asian countries since the fifteenth century for the treatment of disease conditions (in TCM theory) such as impotence, seminal emission, infertility, general weakness with lassitude of the loins and knees, and chronic constipation.
As described in the Chinese Pharmacopoeia, Cistanches Herba is effective in tonifying brain and kidney yang, benefiting essence and blood, and lubricating the intestines. As a tonic, Herba Cistanches ("Rou Cong Rong" in Chinese) has been used for chronic renal disease, impotence, female infertility, morbid leucorrhea, profuse menorrhagia, and senile constipation.
Orobanche species proper (the "Lie Dang" or "Cao Cong Rong" in TCM) were also recorded in classical Chinese pharmacopeias. Orobanche-derived herbal drugs are documented under different names in many well-known medicinal books, including Tang Ben Cao (659 CE, Tang Dynasty), Ri Hua Zi Ben Cao (907–960 CE), Kai Bao Ben Cao (973 CE, Song Dynasty), and Ben Cao Gang Mu (1578 CE).
2.2 Tibetan Medicine
Orobanche species in Tibetan medicine (known as Gro shang rtse) are used to warm the kidneys, treating impotence, kidney and lower back pain, and to strengthen the back and joints. Tibetan practitioners have also traditionally applied broomrape topically for burns.
2.3 European Herbal Tradition
The plant has astringent properties, which explains why it was used in traditional medicine for wound healing. The English herbalist Nicholas Culpeper, writing in his Herball in the 17th century, noted that "the decoction thereof in wine, is thought to be as effectual to void the stone in the kidney and bladder, and to provoke urine, as the broom itself."
2.4 North American Indigenous Use
Several North American Orobanche species have documented ethnobotanical uses. Naked Broomrape was used historically by some North American tribes for externally treating ulcers and cancerous growths, and internally for treating some bowel disorders. California Broomrape or cancer root is used externally to treat skin infections caused by Streptococcus, as a poultice or wash for wounds, ulcers, and herpes lesions. Additional documented indigenous uses include: Blackfoot use of chewed Orobanche fasciculata root blown onto wounds; Keres use of roots as a lung medicine; and Montana Indian use of the parasite on sweet sage roots as a cancer treatment.
2.5 Food Use
Current knowledge suggests that crenate broomrape (Orobanche crenata) could be a refined food with interesting nutritional traits, including high fibre content, good antioxidant capacity, and presence of polyphenols such as verbascoside. Indigenous North American groups also consumed species of Orobanche as food. The Navajo, Ramah people roasted the plant in ashes, peeled the skin off and ate it like a baked potato.
3. Key Constituents and Active Compounds
3.1 Chemical Profile Overview
More than 200 compounds have been identified from Cistanche Herb plants, with the major components including phenylethanoid glycosides (PhGs), oligosaccharides, polysaccharides, essential oils, cistanosides, iridoids, lignans, and alditols.
3.2 Phenylethanoid Glycosides (PhGs)
PhGs are the principal bioactive class and the basis for most standardization. Five PhGs — namely echinacoside, cistanoside A, acteoside, isoacteoside, and 2′-acetylacteoside — have been separated and purified using high-speed counter-current chromatography (HSCCC).
- Echinacoside (ECH): The most abundant and extensively studied PhG. Echinacoside has numerous pharmacological effects, such as antioxidation, anti-senescence, neuroprotection, anti-inflammation, promotion of cicatrization, hepatoprotection, promotion of bone formation, and anti-tumor activities.
- Acteoside (verbascoside): Acteoside, also known as verbascoside, has demonstrated neuroprotection and memory improvement activities by reducing the apoptosis of neurons and loss of memory associated with the combined induction of D-galactose and AlCl₃ in a mouse model of aging.
- Cistanoside A, isoacteoside, 2′-acetylacteoside, tubulosides A and B: Additional bioactive PhGs. In vitro experiments have revealed that tubuloside A modulates oxidative stress pathways to delay cellular senescence, while tubuloside B attenuates neuronal apoptosis through mitochondrial pathway regulation.
PhGs with direct lifespan elongation effects or potential anti-aging properties mainly include echinacoside, acteoside, isoacteoside, and tubuloside, which are known as the most important components of PhGs.
3.3 Polysaccharides
For Cistanche, polysaccharide content reaches up to 13% in C. deserticola and 8.44–10.36% in C. tubulosa. Long-term studies have shown that Cistanche polysaccharide is the basis for Cistanche to play an immunomodulatory role, promoting lymphocyte proliferation and enhancing phagocyte activity.
3.4 Other Compound Classes
Chemical constituents also include volatile oils, non-volatile phenylethanoid glycosides (PhGs), iridoids, lignans, alditols, oligosaccharides, and polysaccharides. The oligosaccharides (e.g., fructooligosaccharides) are associated with prebiotic and laxative effects. Iridoids and lignans contribute additional antioxidant and hepatoprotective activity.
3.5 Phytochemistry of Orobanche spp.
More than 160 compounds have been isolated and identified from Orobanche spp. These include PhGs (notably verbascoside/acteoside, which is shared with Cistanche), flavonoids, iridoid glycosides, and organic acids. Orobanche spp. have a long history of medicinal use with many pharmacological activities; in particular, the extracts show antioxidant activities.
4. Mechanisms of Action
4.1 Neuroprotective Mechanisms
Echinacoside (ECH) can improve neurodegenerative diseases by regulating target genes or target proteins involved in abnormal accumulation of amyloid-β plaques, oxidative stress, apoptosis, and neurotoxicity signaling pathways.
A key mechanism involves the inhibition of excitotoxic glutamate release. Echinacoside inhibited Ca²⁺-dependent 4-aminopyridine-evoked glutamate release in a concentration-dependent manner, and also reduced the 4-aminopyridine-evoked increase in cytoplasmic free Ca²⁺ concentration. This is mediated partly by blockade of voltage-gated N-type and P/Q-type calcium channels.
Echinacoside exerts antiepileptic and neuroprotective actions in a kainic acid rat model through suppressing inflammatory response and activating the Akt/GSK3β signaling pathway.
Echinacoside can reduce MDA content and improve the activities of SOD and GSH-Px in ischemic brain injury; molecular docking analysis has indicated that echinacoside may bind to Keap-1, leading to Nrf-2 nuclear translocation. This Nrf-2 pathway activation is a major antioxidant defense mechanism.
4.2 Androgen/Reproductive Mechanisms
Echinacoside was distributed to the hypothalamus rather than to the testes, suggesting an indirect effect on the testes; ECH directly inhibited hypothalamic androgen receptor (AR) activity, AR translocation to the nucleus, and HPG-axis related gene expression.
In rat studies, the serum level of progesterone and testosterone in rats was increased by Cistanche tubulosa ethanol extract (CTE) administration, and expression of CYP11A1, CYP17A1, and CYP3A4 was enhanced by CTE.
4.3 Immunomodulatory Mechanisms
In a dose-dependent manner, Cistanche polysaccharides (WPCD) significantly promoted the maturation and function of murine marrow-derived dendritic cells through up-regulating the expression levels of MHC-II, CD86, CD80, and CD40, allogenic T cell proliferation, and the yields of IL-12 and TNF-α via toll-like receptor 4 (TLR4).
4.4 Bone Metabolism Mechanisms
Total glycosides and polysaccharides significantly decreased the expressions of RANKL and p-β-catenin, and up-regulated the expression of BMP-2, OCN, OPG, and p-GSK-3β (Ser9); their therapeutic effect on osteoporosis is via activating the Wnt/β-catenin signaling pathway, in accordance with the TCM principle of "tonifying kidney and strengthening bone."
4.5 Gut-Brain Axis
Emerging mechanistic evidence points to a gut microbiota–fatty acid–neuroinflammation axis. Total glycosides from C. tubulosa (GCT) treatment significantly improved spatial memory and reduced amyloid-β burden in APP/PS1 mice; multi-omics analyses revealed that GCT rapidly enriched beneficial taxa like Akkermansia and suppressed Firmicutes, leading to increased neuroprotective short-chain fatty acids (e.g., β-hydroxybutyrate) and decreased pro-inflammatory long-chain fatty acids in both serum and brain.
5. Scientific Evidence by Area of Use
5.1 Cognitive Function and Neurodegenerative Disease
5.1.1 Alzheimer's Disease — Clinical Evidence
An open-label, non-placebo-controlled clinical study on Cistanche tubulosa glycosides (CTG capsule, Memoregain®) for treatment of moderate AD enrolled 18 patients who were administered two 300 mg CTG capsules three times per day; efficacy was assessed by ADAS-cog, MMSE, Activities of Daily Living (ADLs), Blessed Behavioral Scale, and Clinical Global Impression scales. Cistanche extract supplementation for 48 weeks at 300 mg/d was effective in improving cognitive function in subjects with moderate Alzheimer's disease. The study's limitations are significant: it was non-randomized, unblinded, and included only 18 participants, preventing definitive causal conclusions.
5.1.2 Cognitive Function in Healthy Adults — Clinical Evidence
A randomized, double-blind, placebo-controlled trial examined a botanical product containing Cistanche tubulosa and Ginkgo biloba (CG) extracts; 117 healthy participants aged 30–65 years were randomized to receive either CG tablets or placebo for 30 days, with clinical memory assessments and MRI scans conducted at baseline and post-intervention. The results demonstrated that CG tablets significantly improved cognitive performance, evidenced by increased scores in directional memory, associative learning, graphic free recall, and portrait memory subtests of the Clinical Memory Scale. Limitation: Because the product combined Cistanche with Ginkgo, the independent contribution of Cistanche alone cannot be isolated.
5.1.3 Animal and In Vitro Evidence
C. tubulosa extracts containing ECH and acteoside ameliorated cognitive dysfunction caused by amyloid-β-42 via blocking amyloid deposition, and reversing cholinergic and hippocampal dopaminergic neuronal function. Echinacoside improved neuropathological status in mice with Parkinson's disease via neuroprotection and inhibition of activated microglia-mediated NLRP3, Caspase-1, and IL-1β signals of inflammation. Animal and cell-based evidence is extensive, but human trial evidence remains limited.
5.2 Fatigue and Quality of Life
A randomized, double-blind, placebo-controlled clinical trial evaluated a botanical product containing cistanche and ginkgo extracts on adults with chronic fatigue syndrome (CFS); 190 subjects (35–60 years old) were randomized to receive one tablet of a low dose (120 mg ginkgo and 300 mg cistanche), a high dose (180 mg ginkgo and 450 mg cistanche), or a placebo once daily for 60 days. CFS symptoms of impaired memory or concentration, physical fatigue, unrefreshing sleep, and post-exertional malaise were significantly improved (p < 0.001) in both treatment groups. As above, the combination formulation limits attribution to cistanche alone.
A non-controlled open study in elderly Japanese subjects taking Cistanche deserticola extract reported that subjective symptoms of "tired eyes" and "feeling tired all the time" were significantly improved; measures of immune function, arteriosclerosis, and vascular age were significantly improved; no severe adverse effects were caused by the test product. This study's non-controlled design severely limits interpretation.
5.3 Male Reproductive Function and Testosterone
Evidence in this area consists almost entirely of preclinical animal and mechanistic studies. In a rat model: rats fed different doses of CTE (0.2, 0.4, and 0.8 g/kg) by intragastric administration for 20 days showed that administration of CTE at 0.4 and 0.8 g/kg increased sperm count (2.3- and 2.7-fold) and sperm motility (1.3- and 1.4-fold) and decreased the proportion of abnormal sperm. A mechanism-focused study demonstrated that: Cistanche extracts protect against sperm damage in mice and echinacoside (ECH) is one of the major active components; ECH reverses or protects against oligoasthenospermia in rats. No well-controlled human clinical trials on testosterone or male reproductive outcomes for cistanche as a solo supplement had been published at the time this article was written.
5.4 Bone Health
Animal evidence suggests meaningful anti-osteoporotic activity. Total glycosides (TGs) and polysaccharides (PSs) from C. deserticola ameliorated bone histopathological damage, promoted the formation of new bone, collagenous fiber, and chondrocytes, and accelerated the calcium deposits. This work was conducted in SAMP6 (senescence-accelerated mouse prone 6) mice, a recognized osteoporosis model, and is entirely preclinical.
5.5 Immune Modulation
Polysaccharides of Cistanche deserticola have been shown to act as a safe and effective vaccine adjuvant for eliciting both humoral immunity and cellular immunity by activating dendritic cells via TLR4 signaling pathway, in combined in vitro and murine in vivo experiments. In cyclophosphamide-induced immunosuppressed mice, wine-processed polysaccharide administration showed superior immunomodulatory effects: it significantly improved spleen and thymus indices, elevated serum IL-2, IFN-γ, IgA, and IgM levels, and increased the CD4+/CD8+ ratio. No human clinical trial evidence on immunomodulation by cistanche as a sole supplement is currently available.
5.6 Hepatoprotection
A methanolic extract from fresh stems of Cistanche tubulosa was used to study the protective effect of PhG on the liver using a model of liver damage caused by D-galactosamine/lipopolysaccharide; PhG was found to inhibit hepatocyte death by reducing the toxic effect of TNF-α, supporting a hepatoprotective effect in vivo. All hepatoprotective evidence is preclinical (animal model or in vitro). Human data are absent.
5.7 Antitumor Effects
Modern pharmacological studies have shown that Cistanche tubulosa phenylethanoid glycosides (CTPG) have anti-tumor effects on a variety of tumor cells; CTPG can inhibit the normal growth of HepG2 and BEL-7404 cells by inducing cell cycle arrest and apoptosis. Echinacoside has been shown to inhibit the proliferation of pancreatic cancer cells by promoting apoptosis, and ECH inhibits tumor cell growth by regulating MAPK activity. All antitumor evidence is preclinical; no human clinical trials have been conducted.
5.8 Skin and Anti-Aging
In one study, Cistanche deserticola polysaccharide (CDP), a natural anti-inflammatory component, was investigated for its effects on the progression of senescence in human dermal fibroblasts. This was a cell-based in vitro study. The anti-aging effect of echinacoside has been shown in mice and cells, and it also has several anti-aging related effects, which supports its clinical application as an anti-aging drug. Human clinical evidence for dermatological or anti-aging applications is currently absent.
6. Body Systems and Health Areas
The following body systems are associated with broomrape (Cistanche spp.) in the scientific literature:
- Central Nervous System — neuroprotection, cognition, Alzheimer's disease, Parkinson's disease, anti-depression (animal data), stroke recovery
- Male Reproductive System — sperm parameters, testosterone regulation, erectile function (traditional use; preclinical data only)
- Musculoskeletal System (Bone) — anti-osteoporotic activity via Wnt/β-catenin; preclinical
- Immune System — dendritic cell maturation, T and B cell activation, cytokine modulation; preclinical
- Gastrointestinal Tract — laxative/motility effects, prebiotic modulation of gut microbiota
- Liver — hepatoprotection; preclinical
- Skin — anti-senescent effects on fibroblasts; in vitro only
- Energy/Fatigue — anti-fatigue effects; limited human evidence (combination product)
Studies have shown that individual or mixtures of Cistanche-derived phenylethanoid glycosides have anti-tumor activities, in addition to their anti-inflammatory, anti-aging, anti-fatigue, liver-protective, and immunomodulatory properties.
7. Dosage Forms and Reported Dosages
Dosages used in human studies and pharmaceutical applications are as follows:
- In the Memoregain® Alzheimer's disease clinical trial, each patient was administered two 300 mg Cistanche tubulosa glycosides capsules three times per day for 48 weeks (total daily dose: 1,800 mg).
- An integrated analysis of three vascular dementia studies covered 1,076 patients treated with the proposed novel food at a daily dose of 1,800 mg; the applicant proposes a maximum daily intake of 2 g for food supplements.
- In the CFS randomized controlled trial, subjects received one tablet of either a low dose (300 mg cistanche) or high dose (450 mg cistanche), in combination with ginkgo, once daily for 60 days.
- In traditional Chinese regimens, the herb is applied as a tonic or is included as one nutrient in a formula.
- In the rat reproductive study, rats were fed CTE at doses of 0.2, 0.4, and 0.8 g/kg by intragastric administration for 20 days. These are animal doses and are not directly translatable to human dosing.
Note: Human effective dose ranges for most applications other than vascular dementia and CFS remain undefined by controlled clinical trials.
8. Safety Considerations
8.1 EFSA Novel Food Safety Review
The EFSA Panel on Nutrition, Novel Foods and Food Allergens was asked to deliver an opinion on water extract of Cistanche tubulosa stems as a novel food for use in food supplements and foods for special medical purposes; the target population proposed is the general adult population excluding pregnant and lactating women.
The Panel noted that an integrated analysis of three studies covering 1,076 patients with vascular dementia treated at a daily dose of 1,800 mg reported that 12 adverse events were classified as 'definitely', 'probably', or 'possibly related' to exposure; two of these adverse events were classified as severe (cerebral haemorrhage and epilepsy). The Panel considers that the reported adverse events raise safety concerns.
The Panel also noted the limitations of the toxicological studies, in particular the non-compliance with the EFSA approach on genotoxicity testing strategy and the non-compliance with good laboratory practice (GLP); in view of the adverse events in the human studies, the Panel considers that additional toxicological studies following testing guidelines would not be able to overcome the concerns raised from the human studies.
8.2 Genotoxicity Assessment (Memoregain®)
The Cistanche tubulosa extract product Memoregain® did not induce genotoxicity in the Ames test up to 5 mg/plate; did not induce chromosomal aberrations in CHO-K1 cells up to 2.5 mg/mL; and did not induce micronucleus formation in the bone marrow of mice up to 500 mg/kg. In a 28-day repeated toxicity study, the NOAEL for Memoregain® was greater than 500 mg/kg body weight/day in rats.
8.3 CYP Enzyme Interaction Potential
Results of immunohistochemistry and western blot analysis confirmed that the expression of CYP11A1, CYP17A1, and CYP3A4 was enhanced by CTE administration in rats. CYP3A4 is the major hepatic drug-metabolizing enzyme responsible for the clearance of a large proportion of pharmaceutical drugs. Induction of CYP3A4 by Cistanche constituents raises the theoretical concern of altered plasma levels of co-administered CYP3A4 substrates, though direct human pharmacokinetic interaction studies have not been published.
Additionally, acteoside from C. tubulosa has been identified computationally as a potential modulator of CYP3A4, CYP19A1, and CYP2E1 enzymes. Several key enzymes, including CYP3A4, CYP19A1, CYP2E1, TNF, BCL-2, RYR2, and ATP2A1, were identified as potential targets underlying the effects of acteoside.
8.4 Endangered Species Concern
Cistanche deserticola is an endangered plant, which is why many cistanche supplement manufacturers do not use it. Consumers and manufacturers should ensure product sourcing is from cultivated C. tubulosa or authorized cultivation programs to avoid contributing to species depletion.
8.5 Traditional Contraindications
According to Traditional Chinese Medical theories, Cistanche's nature and flavour is sweet, salty, and warm, going into kidney and large intestine meridians; it is commonly used to invigorate the renal function, nourish essence and blood in the treatment of lumbar debility, impotence, infertility, and muscle weakness, and to regulate the intestinal tract environment. TCM practice traditionally contraindicates warming kidney tonics in individuals with heat-excess patterns; however, these classical contraindications have not been formally validated in controlled human trials.
9. Summary of Evidence Strength
- Cognitive function (Alzheimer's/vascular dementia): Weak-to-moderate; one small open-label study (n=18) and one RCT using a combination product; extensive preclinical support.
- Chronic fatigue: One placebo-controlled RCT (n=190), but using a combination formulation; cannot isolate cistanche's independent effect.
- Male reproductive/testosterone: Preclinical (rat) only; no human RCT evidence.
- Bone health: Preclinical (mouse model) only.
- Immune modulation: Preclinical (in vitro and murine) only.
- Hepatoprotection: Preclinical only.
- Antitumor: Preclinical only; no clinical trial data.
- Anti-aging/skin: In vitro and animal only.
Overall, the strongest human evidence for Cistanche as a supplement pertains to cognitive support in dementia patients, where it has been authorized as a prescription drug in China for vascular dementia. For all other indicated uses, current evidence is at the preclinical stage, and independent well-powered human RCTs are lacking.
References
Go back